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Background aims. With the rising use of umbilical cord blood (UCB) as an alternative source of hematopoietic stem cells,
storage inventories of UCB have grown, giving rise to genetically diverse inventories globally. In the absence of reliable
markers such as CD34 or counts of colony-forming units, total nucleated cell (TNC) counts are often used as an indicator of
potency, and transplant centers worldwide often select units with the largest counts of TNC. As a result, cord blood banks
are driven to increase the quality of stored inventories by increasing the TNC count of products stored. However, these
banks face challenges in recovering consistent levels of TNC with the use of the standard protocols of automated umbilical
cord processing systems, particularly in the presence of input variation both of cord blood volume and TNC count, in which
it is currently not possible to process larger but useable UCB units with consequent losses in TNC. Methods. This report
addresses the challenge of recovering consistently high TNC yields in volume reduction by proposing and validating an
alternative protocol capable of processing a larger range of units more reliably. Results. This work demonstrates improve-
ments in plastic ware and tubing sets and in the recovery process protocol with consequent productivity gains in TNC yield
and a reduction in standard deviation. Conclusions. This work could pave the way for cord blood banks to improve UCB
processing and increase efﬁciency through higher yields and lower costs.
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With the rising use of umbilical cord blood (UCB) as
a source of hematopoietic stem cells (HSC), storage
inventories of have grown, giving rise to vast
numbers of genetically diverse UCB units to provide
an alternative when an adult peripheral blood stem
cell or bone marrow donor cannot be found. This
alternate product is “off the shelf” and is pre-estab-
lished as “ﬁt for use” through process control and
qualiﬁcation. Querol et al. [1] illustrate that UCB
users rely on the rigorous assessment carried out in
banks to avoid poor engraftment after thaw and that
correlated attributes such as total nucleated cell
(TNC) count is used as a surrogate of graft potency
in the absence of a better marker such as CD34,
colony-forming units (CFU) or cellular viabilities
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plantation, the hematopoietic potential of UCB is
proportional to the TNC count and thus correlates to
transplantation end points [2,3]. It is challenging for
public cord blood banks to remain economically
viable because UCB utilization rates are relatively
low compared with inventory size, being reported as
between 3e4% across World Marrow Donor Asso-
ciation and the US National Marrow Donor Pro-
gram registries [4]. Howard et al. [5] analyzed the
cost-effectiveness of banks on the basis of inventory
size, which serves to illustrate the requirement of the
niche that UCB transplantation currently populates.
Therefore, despite that the majority of units will
never be utilized, the statistical relevance of such
inventories is required to overcome the current un-
met need as a result of human leukocyte antigenchE, Centre for Biological Engineering, Healthcare Engineering Research
illiams2@lboro.ac.uk
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Improving umbilical cord blood processing 59(HLA) disparity. Querol et al. [6] further examined
this, but, in addition to HLA disparity, also further
discriminated with respect to UCB quality, again
using TNC count as a surrogate marker and illus-
trating that public banking programs should focus on
increasing the quality of banked inventories to miti-
gate the inventory size to remain statistically relevant
while increasing the utilization rate.
When selecting UCB units, transplant centers
will facilitate national registries to perform the
necessary searches that are typically carried out with
the use of complicated algorithms. The Anthony
Nolan search algorithm for a basic UCB unit selec-
tion ﬁrst looks to create a list of units that are greater
than 2.5  107 TNC/kg for a single or 1.5  107
TNC/kg for a double, ranked initially by 6/6, 5/6 and
ﬁnally 4/6 HLA-matched. Howard et al. explain that
UCB utilization is sensitive to the selection process,
whereas Lee et al. [4] describe the need to gain the
transplant physicians’ trust; both illustrate that the
individual preferences of transplant centers also have
an impact on unit selection. Units will be ranked by
HLA (ﬁrst HLA-C matching at antigen level, double
mismatches at the same locus on HLA class I, high-
resolution matching in HLA class I loci and mother’s
HLA typing: Non Inherited Maternal Antigen
(NIMA) match to prefer and Inherited Paternal
Antigen (IPA) mismatch to be avoided), CD34 dose,
CFU/viability, red blood cell (RBC) depletion during
cell processing and ﬁnally, ethnicity. Such algorithms
put the greatest onus on TNC dose above any other
cellular attribute. Barker et al. [7] concluded that
TNC count is of critical importance in predicting
graft success alongside HLA disparity and that
increasing TNC dose can mitigate the disadvantages
of a greater HLA disparity at 5/6 level match.
Despite the fact that the only accepted in vitro
measure for engraftment is a CFU assay [2] and that
markers such as CD34þ have proven to be predictive
of engraftment [8], these factors are not weighted
highly in selection algorithms; as a result of this,
UCBs are driven to increase the quality of stored
inventories by increasing the TNC counts.
This is challenging in the presence of process input
variation as represented by differences in the blood
volume of collected UCBs and TNC count. In some
cases collected UCBs and consequent TNC counts
are too large to be processed with current protocols.
There are 2 methods of increasing the TNC count
of products, the ﬁrst being increasing the total num-
ber of TNC collected during the procurement of the
UCB. This has proven to be highly dependent on the
competency of the individual collecting the blood.
For this reason, the Anthony Nolan Cell Therapy
Centre (ANCTC) adopted a system of highly trained
collectors. The level of “uncollected” blood in theplacenta is not known, and therefore any improve-
ments in the procurement would need to be evalu-
ated. The second method, the focus of this
investigation, is to reduce the TNC loss by improved
processing and reduction in wastage of collected
UCBs. No system recovers 100% of the TNC. The
ANCTC has implemented the Sepax System (Biosafe
SA, Eysins, Switzerland) which is well suited to UCB
processing. The system is capable of high recoveries
[9] while being a functionally closed processing sys-
tem. All aspects of the separation phases are auto-
mated and therefore not subject to user variability.
The ANCTC opted for a non-hydroxyethyl starch
procedure to better control the process. By not adding
anything during the process (other than the cryopro-
tectant), the risk of contamination is minimized, the
processing costs are reduced and the risk of undesir-
able side effects is eliminated [10]. Initial data showed
that processing with and without non-hydroxyethyl
starch was comparable with well-controlled units
(shipment time and temperature) (unpublished data);
the ANCTC already has stringent procedures con-
trolling this. However, it was observed that the yields
of TNC recovered after processing tended to be lower
for larger UCB units, for example, those with higher
TNC counts before processing (Figure 1).
Figure 1 shows the correlation of median yields
and ranges of recoveredTNCwith respect to the range
of TNC count before processing. At the ANCTC,
Only UCB units with TNC count of at least 1200 
106 are processed, whereas UCB units with a TNC
count of at least 1500 106 are deﬁned as large UCB
units. It has been observed that as the range of TNC
increases, the recovered percentage of TNC de-
creases. Moreover, the maximum and minimum
percentages of recovered TNC range widely, from as
low as approximately 40% to as high as nearly 120%.
This is inhibitory to the effectiveness of a cord
blood bank. Despite the quality of the input product,
the ﬁnal product is consequently limited to a partic-
ular repertoire of potential recipients. An increase in
transplant-related mortality rate has been observed in
children transplanted with a low UCB dose [11].
Assuming a minimal cell dose of >3  107/kg, an
average ﬁnal TNC count of 120  107 would be
suitable for a patient weighing approximately 40 kg,
typically a prepubescent child according to the Royal
College of Paediatrics and Child Health. High losses
of TNC during processing would mean that the ﬁnal
cell dose is insufﬁcient and consequently, potentially
ineffective, for many of the patients. The impact of
this is somewhat reduced by the potential for double
UCB transplants, but, as the processing facility with
responsibility for the quality of the products stored as
detailed previously, it is imperative to strive to
improve the processing system to maximize the yield
Figure 1. Median TNC yield for different ranges of TNC with the use of a protocol on Sepax.
60 M. W. Naing et al.from every unit. Given that UCB selection criteria
stipulate a minimum cell dose per kilogram, reducing
cellular attrition during collection can radically
change the repertoire of patients for whom the
collected UCB is suitable. This is particularly relevant
for large units, deﬁned by the ANCTC as UCB units
with TNC count >1500  106 cells, which have re-
covery rates of 75% (Figure 1).Variability in incoming UCB units
One of the major challenges in processing of bio-
logical materials for clinical applications is main-
taining quality standards in the face of large
variations in the input to the process. In the case of
processing UCB for banking, banks must contend
with the variability of incoming UCB units in terms
of volumes as well as TNC counts. An analysis of the
1839 UCB units collected by the ANCTC between
December 2008 and June 2012 shows that there is a
wide distribution of the UCB units collected in terms
of TNC counts and volume (Figure 2A,B). The
mean TNC count was 1086  106 cells, with a
standard deviation of 651  106 cells; the mean
volume was 93.6 mL, with a standard deviation of
13.9 mL. There may be a relationship between vol-
ume of the UCB unit and the number of TNC within
the unit (Figure 2C).
Hematocrit of the samples ranged from approxi-
mately 10e50%, with a mean value of 36.3% and a
standard deviation of 5.15%. There are also many
variations in other factors such as platelet counts, pro-
portion of CD34þ cells to TNC, proportions of
mononuclear cells (MNC) to TNC, and number of
nucleated red blood cells. All or a combination of some
of these factorsmay contribute toprocessing outcomes.As seen in Figure 1, as the size of the UCB unit
measured in TNC increases, the yields drop, with
units of UCB 1800  106 faring poorly after pro-
cessing with yields of <70%. Taking these factors
into consideration, this work seeks to test the theory
that 21 mL (a standard volume for volume-reduced
UCB) is the optimal ﬁnal volume for all UCB units
regardless of the initial number of TNC or initial
collected volume. Previously, Papassavas et al. [12]
have shown that with the use of the Sepax system,
splitting large units of UCB into 2 smaller volume
units before processing increased TNC, mono-
nuclear and CD34þ recoveries. Solves et al. [13] also
showed that in systems other than Sepax, the in-
crease in volume of buffy coat collected increased the
yield of TNC.
It has been hypothesized that units of UCB
centrifuged at similar speeds and durations (adjusted
for volume as in the protocols used in Sepax) will
produce different volumes of packed TNC,
depending on the actual initial number of TNC, that
is, a unit with a higher number of TNC should result
in a higher volume of buffy coat. Coupled with the
results shown in Figure 1, it has been hypothesized
that for larger UCB units (>1500  106 TNC), the
yield of TNC can be improved by increasing the ﬁnal
buffy coat volume collected. The ANCTC is already
in operation with established protocols in line with
internationally accepted standards for UCB banking.
Hence, it is imperative that any new protocols must
be minimally disruptive to standard operating pro-
cedures and must not deviate from already-estab-
lished measures for quality control. To do this in line
with these current protocols, it has been proposed to
collect 2 volumes of 21 mL each from each UCB
unit. However, initial experiments showed that
Figure 2. Histograms show distribution of (A) TNC counts of the incoming UCB units, (B) volume of the incoming UCB units and
(C) relationship between volume and TNC count; n ¼ 1839.
Improving umbilical cord blood processing 61collecting a total of 42 mL does not accommodate
buffy coat separation well because the volume itself is
too large for effective removal of RBCs. After this, a
series of in-house experiments further indicated that
30 mL may be a more optimal volume for buffy coat
collection. Hence, it is proposed that 30 mL is
collected through the use of the system, and the unit
is topped up to 42 mL by use of the volume of plasma
collected during the buffy coat separation.For this study, the Sepax 1 was used for the
majority of the dataset. Part-way through the study,
Biosafe provided the use of a Sepax 2 for the pur-
poses of evaluating process optimization. The Sepax
2 is functionally the same as the Sepax 1, with
changes to the user interface and a better module for
traceability. A small sample set was processed on the
Sepax 2 according to the same process methodolo-
gies to conﬁrm this.
62 M. W. Naing et al.For validation purposes, 30 UCB units with
TNC counts ranging from 735  106 to 2344  106
were processed over a period of 6 months between
June 2012 and December 2012 with the use of this
new setup and protocol.Methods
Because the purpose of the improvement project was
to allow for rapid implementation on successful
validation, it was crucial that as far as possible, the
experimental protocols follow the clinical unit pro-
cessing protocol. Hence, in selecting the UCB unit
for the validation exercise, the following criteria were
used in accordance with ANCTC standards: (i)
input TNC must be >600 and (ii) UCB units must
be <33 hours old at the time of processing.
Because the aim of this work was to recover a
higher percentage of TNC from large units, wherever
possible, units with counts >1500  106 TNC were
used. The units used for this validation have been
rejected for clinical use because they fell under
exclusion criteria such as the mother having under-
gone hormone treatments. All units used had been
consented for research before the validation experi-
ments. To comply with the current regulatory
framework for cord blood banks, all processing was
carried out in C-grade Good Manufacturing Practice
facilities and quality control tests were performed in
class II laboratory facilities according to the current
standard operations procedures for processing of
UCB for clinical use within the ANCTC.Initial counts
All UCB units to be used in the validation were
processed under the same protocol for clinical units
for reception and initial sampling. The UCB unit was
weighed and passed into the processing room, where
a sample bubble was attached to the UCB unit by
means of the total containment device. The unit was
then placed onto the shaker for 10 min before a
sample calibrator (calibrated for 1mL) was used to
transfer 1 mL of UCB to the sample bubble. The
sample bubble was then sealed with the use of a tube
sealer.
The sample was transferred to the quality control
laboratory, where the cell count for TNC was per-
formed with the use of a Sysmex XE-2100 Auto-
mated Hematology System (Sysmex UK Ltd, Milton
Keynes, UK). The following parameters were
recorded into the database: bar code, date, time of
reception, weight, volume, TNC count, percentages
of neutrophils, leukocytes and monocytes, number of
nucleated red blood cells and hematocrit.UCB volume reduction with the use of the Sepax system
Before volume reduction with the use of the Sepax
system, another sample of approximately 0.5 mL
was taken as a control and stored in the processing
room. Because the volume to be collected (30 mL)
exceeded the ﬁll volume of the ﬁnal bag on in the
manufacturer’s kit (maximum volume ¼ 25 mL),
the Sepax single-use kit CS-540.4 (Biosafe SA,
Eysins, Switzerland) was modiﬁed by removing the
ﬁnal bag and substituting with an Eva double kit
(Macopharma, Twickenham, UK) (Figure 3). The
Eva double kit has 2 bags with a ﬁll volume of up to
30 mL each. The Eva double kit has individual
clamps on the tubing leading to each bag and hence
makes it possible to collect and analyze the different
volumes collected during the 2 separate rounds of
buffy coat collections according to Sepax protocol.
The 2 Eva bags were labeled as buffy coat bag 1
(BC1) and buffy coat bag 2 (BC2). The modiﬁed kit
was mounted into the system according to standard
operating procedure, in accordance with the in-
structions in the manufacturer’s manual. On Sepax,
the level of sensitivity was set to 3 (high) and the
volume of buffy coat to be collected was set to 30
mL, as mentioned previously. All other settings
remained unchanged. Checks were performed to
ensure that all connections were secure and that
there were no leakages. Once the initial vacuuming of
the kit was done by the system, the clamp on BC2
was closed off. As a result, the extracted buffy coat
after the ﬁrst sedimentation ﬂowed only into BC1.
During the second phase of sedimentation, the
clamp of BC1 was closed off and that of BC2 was
opened such that the buffy coat from the second
separation only ﬂowed into BC2.
Once the run was completed, the kit was removed
according to Sepax protocol. Each bag (plasma bag,
RBC bag, BC1 and BC2) was sealed and placed on
the shaker for at least 10 min to ensure that contents
were homogeneous. The RBC bag, BC1 and BC2
were weighed, and weights were recorded. In a
biosafety cabinet, 0.5 mL of each sample from all of
the 4 bags were taken and transferred into sample
tubes. The control sample (taken before processing)
was also transferred to a sample tube. The contents
of BC1 and BC2 were combined, and the weight was
recorded. A 1-mL sample was taken from this bag as
the ﬁnal sample. All the sample tubes were trans-
ferred to the quality control laboratory for analysis.Quality control analysis
Table I summarizes thequality control analysis carried
out on each UCB. TNC counts were performed on all
samples including control samples and samples drawn
Figure 3. (A) Macopharma Eva double kit and (B) Sepax single-use kit CS504.1 attached to Macopharma Eva double kit.
Improving umbilical cord blood processing 63from plasma bags. Flow cytometry analysis and CFU
assays, currently the only accepted in vitromeasure for
engraftment [2], were only performed for control
samples and ﬁnal samples.Flow cytometry protocol (ﬂuorescence-activated cell
sorting)
With the use of the values from the TNC count, the
volume of blood necessary to add 0.6  106 cells to a
ﬂuorescence-activated cell sorting (FACS) tube was
calculated. If the total RBC count in the tubeexceeded 175,000  103, the calculated volume of
blood was reduced accordingly to ensure that com-
plete lysis of red cells occurred in the assay. Each
TruCOUNT tube was labeled with the sample
identiﬁcation and checked to ensure that the
microbead pellet was intact and contained within the
metal retainer at the bottom of the tube. In a
biosafety cabinet, the volume of cells required was
added onto the side of the tube just above the
retainer and topped up to 50 mL with FACS buffer;
50 mL of the ﬂuorescein isothiocyanate antibody
cocktail was added to each tube. The tubes were
Table I. Summary of quality control analysis for validation units.
Sysmex
(TNC)
FACS
(CD45/CD34) CFU assay
Initial quality control Yes e e
Control Yes Yes Yes
Buffy coat 1 (BC1) Yes e e
Buffy coat 2 (BC2) Yes e e
Final Yes Yes Yes
RBC bag Yes e e
Plasma bag Yes e e
64 M. W. Naing et al.incubated for 15 min in the dark. Lysis solution was
prepared by dilution of Pharm lyse with distilled
water in a centrifugal tube; 900 mL of the lysis solu-
tion was added to the tubes and vortexed gently to
allow mixing. Because of the higher hematocrit of the
samples, the tubes were incubated for 10 min at
37C. Subsequently, 5 mL of 7-aminoactinomycin D
(7-AAD) was added to the tube, mixed gently and
allowed to incubate for at least 2 min before being
run on the cytometer.
The FACS results from the control sample and the
ﬁnal sample were compared to ensure that the volume
reductionprocessdoesnot adversely affect the viability
of the CD34þ cells. Within each sample, the CD45
readings from the FACS results were also compared
against TNC readings to check that sampling was
consistent and as a precaution against systematic er-
rors such as machine malfunctions. The counts wereTable II. Summary of results of experimental data compared with clinic
Clinical
(n ¼ 333)
Pre-processing
Volume (mL) 117.8  26.9
TNC  106 1769.4  572.2
MNC  106 933.6  374.2
CD34þ stem
cells  103
6384.5  2909.9
Leukocyte % 36.7  3.9
Monocyte % 10.9  3.3
Granulocyte % 47.3  8.8
Hematocrit % 38.8  4.6
Post-processing
Final volume (mL) 20.5  0.6
TNC recovery (%) 75.2  15.70
MNC recovery (%) 80.8  14.2
CD34þ stem
cell recovery (%)
88.2  21.2
Leukocyte % 39.7  12.4
Monocyte % 17.3  7.2
Granulocyte % 37.4  10.7
Final hematocrit % 37.4  10.2
Viability (%) 97.2  3.7
Values are expressed as mean  standard deviation. Hematocrits of expe
topped up with 12 mL of plasma). Because clonogenic efﬁciency results a
comparison.repeated if the difference between the TNC reading
and the FACS reading was more than 20%.CFU protocol
MethoCult GF (STEMCELL Technologies, Gre-
noble, France) was aliquoted into 3-mL tubes and
stored in the refrigerator. Before starting the assay, the
required number of MethoCultGF aliquots were
removed from the refrigerator and allowed to stand at
room temperature. The FACS results were entered
into the database and used to calculate the volume of
the sample required in microliters for addition to a 3-
mL aliquot of MethoCultGF such that the ﬁnal cell
density was approximately 150 CD 34þ cells per dish.
In a biosafety cabinet, the calculated volume of
the blood sample cell suspension was pitpetted into
the 3-mL tube of MethoCult GF. The sample vol-
ume in each aliquot was subsequently made up to
300 mL with Iscove’s Modiﬁed Dulbecco’s
Medium þ 2% fetal bovine serum. The contents of
the tube were vortexed vigorously until the cells were
evenly suspended, and the tube was left standing for
10 min to allow all bubbles to rise to the surface.
Subsequently, 1.1 mL of the mixture was drawn with
a blunt needle and dispensed into a well of a 6-well
plate. Another 1.1 mL from the same tube was
placed into a well diagonally opposite to the ﬁrst well.
The plate was rotated and tilted to spread the viscousal data.
Experimental
P value(n ¼ 30)
159.4  34.8 <0.001
1816.1  422.2 >0.05
1053.8  419.0 >0.05
6598.3  4570.3 >0.05
35.4  5.4 >0.05
11.1  2.6 >0.05
48.1  5.9 >0.05
39.1  3.4 >0.05
30.4  0.4 Not Applicable
89.3  6.2 <0.001
86.1  6.1 <0.001
97.1  23.7 <0.001
38.0  6.1 >0.05
12.3  3.2 <0.001
42.8  7.2 >0.05
39.2  9.1 >0.05
95.2 8.6 >0.05
rimental validation units are based on 42 mL (30 mL of buffy coat
re not available for all clinical units, n ¼ 144 (clinical units) for this
Figure 4. Chart shows TNC content (expressed in percentage of initial count) in the ﬁrst separation (BC Bag 1), second separation
(BC Bag 2), ﬁnal bag and RBC bag.
Improving umbilical cord blood processing 65mixture evenly across the surface of each dish such
that the meniscus attached to the wall of the dish on
all sides. Both wells were labeled, and the empty
wells in the plate were topped up with sterile water.
The plate was incubated for 14 days at 37C, 5%
CO2 in air and >95% humidity before being
removed from the incubator for counting of colonies.
The counts were recorded in the database, and the
clonogenic efﬁciency of the unit was calculated.Results
Results were analyzed and plotted with the use of
statistical software (SPSS, version 19; SPSS Inc,
Chicago, IL, USA). A total sample of 30 units was
processed and measured with TNC counts ranging
from 735  106 to 2344  106; 20 units were pro-
cessed with the use of Sepax 1, and 10 additional
units were processed with the use of Sepax 2.Figure 5. Charts show the yields of (A) clinical units (mean TNC yield ¼Table II shows the summary of results comparing
clinical data (n ¼ 333) processed up to 2012 and the
experimental units processed with the use of the
modiﬁed double-bag kit (n ¼ 30).
The clinical data set and the experimental dataset
were compared by means of a 2-sample t-test. A
value of P  0.05 was considered signiﬁcant. As
shown in Table II, the mean input volumes for the
experimental dataset were signiﬁcantly higher than
for the clinical dataset (P  0.05). However, after
processing, the recovery rates for TNC, MNCs and
CD34þ progenitor cells were all signiﬁcantly higher
than that of the clinical dataset (P  0.05). We also
noted that the value of the hematocrit in the modiﬁed
protocol did not signiﬁcantly differ from that of the
current clinical protocol.
Figure 4 shows a graphical presentation of dis-
tribution of TNC (in percentages) in 4 bags: ﬁrst
separation (BC1), second separation (BC2), ﬁnal75.2%) and (B) experimental units (mean TNC yield ¼ 89.3%).
Table III. Comparison between Sepax 1 and Sepax 2.
Sepax 1 Sepax 2
P value(n ¼ 20) (n ¼ 10)
Pre-processing
Volume (mL) 143.9  33.8 166.6  36.6 >0.05
TNC count  106 1738.9  459.3 1876.0  371.2 >0.05
MNC  106 912.2  267.1 947.2  186.0 >0.05
CD34þ stem
cells  103
6342.1  2627.3 6469.2  3403.9 >0.05
Leukocyte % 35.7  6.8 34.9  3.5 >0.05
Monocyte % 11.2  2.2 11.1  2.2 >0.05
Granulocyte % 47.5  6.2 49.2  5.1 >0.05
Hematocrit % 39.6  3.3 38.2  3.3 >0.05
First separation
Volume 1 (mL) 18.9  1.7 20.0  0.5 <0.05
TNC recovery (%) 77.4  9.6 80.1  8.7 >0.05
MNC recovery (%) 76.3  9.6 75.3  5.4 >0.05
Leukocyte % 39.8  8.2 36.3  5.8 >0.05
Monocyte % 12.5  2.8 12.6  2.7 >0.05
Granulocyte % 38.3  11.7 38.7  11.3 >0.05
Hematocrit % 53.6  9.3 63.1  5.7 <0.05
Second separation
Volume 2 (mL) 11.4  1.5 10.5  0.3 <0.05
TNC recovery (%) 10.4  3.1 9.5  1.4 >0.05
MNC recovery (%) 6.9  2.1 7.2  1.9 >0.05
Leukocyte % 28.5  9.5 29.3  6.0 >0.05
Monocyte % 7.8  2.9 9.6  1.8 >0.05
Granulocyte % 57.5  11.6 57.0  8.2 >0.05
Hematocrit % 53.6  6.1 60.5  7.8 <0.05
Post-processing
Final combined
volume (mL)
30.3  0.3 30.5  0.5 >0.05
TNC recovery (%) 89.6  6.3 88.8  6.0 >0.05
MNC recovery (%) 87.0  5.8 84.2  8.3 >0.05
CD34þ stem cell
recovery (%)
102.5  23.3 86.4  20.7 >0.05
Leukocyte % 39.8  8.2 36.1  5.7 >0.05
Monocyte % 12.5  2.8 12.4  2.8 >0.05
Granulocyte % 38.3  11.7 44.6  7.4 >0.05
Hematocrit %
(in 30 mL)
53.6  7.2 61.9  4.4 ¼0.001
Hematocrit %
(corrected; 42 mL)
38.6  5.3 40.4  13.9 >0.05
Viability (%) 96.6  1.9 97.0  1.4 >0.05
66 M. W. Naing et al.bag (combined) and RBC bag. Results showed that
the Sepax protocol recovered a higher percentage of
the TNC during the ﬁrst separation than during the
second separation when sensitivity level was set to 3
and the volume of buffy coat was set to 30 mL. For
this particular setting, the ﬁrst separation drew
approximately 18e19 mL, whereas the second sep-
aration drew approximately 11e12 mL. The TNC
counts carried out on plasma bags show that there is
little loss of nucleated cells into the plasma bag,
indicating effective separation of plasma and buffy
coat. However, up to 20% of nucleated cells, mainly
neutrophils, were lost to the RBC bag, with a mean
loss of approximately 7% for each unit of UCB
(Figure 4).
The results of the ﬁnal bag were checked not only
against the values of BC1 and BC2 but also against
that of the RBC bag to ensure that the values were
consistent.
Comparing the results of this protocol with data
collected from clinical units (n ¼ 333), in which
only 21 mL of buffy coat was collected, this work
shows promising results in terms of mean recovery
values and standard deviations (Figure 5). The
mean TNC recovery from cord blood units with
the use of the modiﬁed double-bag method was
>14% higher and the variability in recoveries 2.5-
fold lower (7% compared with 16% coefﬁcient of
variation (CV)). There was no signiﬁcant differ-
ence in the results between the experimental units
and the clinical units in terms of clonogenic efﬁ-
ciency, which shows that this change in method-
ology does not adversely affect the clinical efﬁcacy
of the cells.
Because the ANCTC had recently acquired one
Sepax 2 system from Biosafe, a number of units were
also experimented on Sepax 2 with the use of the
modiﬁed plastic ware and protocol. The same stan-
dard operating procedure was followed as with units
run on Sepax 1. Because of resource constraints,
only a small number of units were run on Sepax 2.
Table III shows a detailed comparison between units
run on Sepax 1 (n ¼ 20) and units run on Sepax 2
(n ¼ 10). Each corresponding set of data was
compared by means of a 2-tailed unpaired t-test.
The results show that in the majority of the pa-
rameters, there were no signiﬁcant differences within
Sepax 1 and Sepax 2. There was no indication that
the different default preset protocols affected the
yield of TNC. Although units were randomly
assigned during the experiment, input values for both
sets of data were comparable. We noted that during
the ﬁrst separation, a higher buffy coat volume was
drawn on Sepax 2 compared with that in Sepax 1.
This may be a result of the enhanced sensitivity of the
new protocol that Sepax 2 is running. We observedthat during the second separation, a smaller volume
was drawn to compensate and make up the correct
amount of the total volume. As a result, the corre-
sponding hematocrit was signiﬁcantly higher in the
ﬁrst separation. Inexplicably, the hematocrit in the
second separation was also signiﬁcantly higher for
Sepax 2. When the ﬁnal volume was adjusted to 42
mL with the addition of 12 mL of plasma, however,
the hematocrit values were comparable between the
2 systems.Conclusions
Many parameters of collected UCB units may vary
largely, depending on factors such as race, size of the
baby, size of the mother, type of birth and so forth. In
Improving umbilical cord blood processing 67the face of such wide variations, it is a challenging
task to reliably and reproducibly process UCB units
such that they are not only optimized for storage but
also matched to the needs of patients in terms of
diversity and size. An ineffective processing method
will reduce the pool of UCB units available for pa-
tients in need because a smaller-than-expected vol-
ume of TNC is recovered; this not only decreases the
quality of individual units but eventually may be
detrimental both to the bank and to the patients.
Because transplant centers regularly pick units with
large TNC counts after processing, only the units
containing the greatest TNC counts are used, and
units with fewer nucleated cells may never be used.
Over a long period of time, this will drive up un-
necessary costs in terms of storage and facility
maintenance, which will in turn be passed on to
transplant centers and ﬁnally to the patients.
The validation shows that MNC and TNC yields
can be increased in a cost-effective manner within
the current Sepax protocol by modifying the process-
ing plastic ware and increasing collection volume
(30 mL), thus standardizing the yields irrespective
of input TNC and/or volume. Furthermore, the yield
ofCD34þ cells is alsomaintained and improved. Even
though Papassavas et al. [6] were successful in splitting
large units into 2 bags to increase recovery, the splitting
method not only increases time spent per unit but also
doubles the consumable costs. With the modiﬁed kit
and protocol presented in this work, the comparable
increase in time and cost aremuch lower for the similar
increases in yields. However, it must be noted that this
method probably only applies to large units, and it is
not the intention that the collection volume for all
UCB should be changed to 30 mL. In conclusion, this
work shows that it is possible to gain high consistent
yields from across all UCB units during volume
reduction without incurring high extra costs and with
minimal disruption to the standard operating pro-
cedures established within the current regulatory
framework.
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